Combination therapy leads to cure of leukemia and lymphoma mice.
(A) SJL mice (10 mice per group) were injected IV (tail vein) with live 105 AML cells on day 0 and subsequently treated with the indicated types of treatment, as described in “Materials and methods.” Mice treated with the combination of chemotherapy plus B7.2-IgG had 50% cure; all other groups developed lethal leukemia. The results are representative of 3 independent experiments. (B) C57BL/6 mice (10 mice per group) were injected SC in the flank with live 106 EL-4 cells and subsequently treated as described in “Materials and methods.” Mice with no treatment, chemotherapy alone, and B7.2-IgG alone, were killed when tumors reached a size of approximately 400 to 600 mm2. In the chemotherapy-plus-B7.2-IgG group, 70% of the mice remained tumor free, and in the chemotherapy-plus-mutated B7.2-IgG group, 60% of the mice remained tumor free. The results are representative of 2 independent experiments. (C) SJL mice (10 mice per group) were injected IV with live 105 SJL Ly cells on day 0 and subsequently treated with the indicated types of treatment, as described in “Materials and methods.” Mice treated with chemotherapy alone had significantly prolonged survival (P < .01), but eventually developed lethal tumors. In the chemotherapy-plus-B7.2–IgG group, 90% of the mice remained tumor free, and in the chemotherapy-plus-B7.1/B7.2–IgG group, 70% of the mice remained tumor free. The results are representative of 2 independent experiments.
